Aptevo Therapeutics (APVO) Cash from Operations (2015 - 2026)
Aptevo Therapeutics (APVO) posted Cash from Operations of 8000000.0 for Q1 2026, down 52.56% sequentially from 5244000.0 in Q4 2025, and down 21.67% YoY from 10213592.23 in Q1 2025.
Aptevo Therapeutics (APVO) Cash from Operations (2015 - 2026) Analysis & Trends
Aptevo Therapeutics has reported Cash from Operations for 12 years, with the latest figure at 8000000.0 in Q1 2026.
- Quarterly Cash from Operations fell 21.67% year-over-year to 8000000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1637000.0 (up 93.1% YoY) and the FY2025 annual result came in at 25600000.0, down 7.63% from the prior year.
- Cash from Operations fell to 8000000.0 in Q1 2026 per APVO's latest filing, from 5244000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 18700000.0 in Q3 2025 and troughed at 8000000.0 in Q1 2026.
- A 5-year average of 3807000.0 and a median of 5759000.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations slumped 245.66% in 2024, then jumped 457.83% in 2025.
- Over 5 years, Cash from Operations stood at 5939000.0 in 2022, then advanced by 12.06% to 5223000.0 in 2023, then declined by 10.26% to 5759000.0 in 2024, then increased by 8.94% to 5244000.0 in 2025, then plunged by 52.56% to 8000000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 8000000.0, 5244000.0, and 18700000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Aptevo Therapeutics | 3.18 Mn | -6.61 Mn | - | -5.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.42 Mn |
| Jun 30, 2026 | -5.42 Mn |
| Mar 31, 2026 | -8.00 Mn |
| Mar 31, 2026 | -8.00 Mn |
| Dec 31, 2025 | -5.24 Mn |
| Dec 31, 2025 | -5.24 Mn |
| Sep 30, 2025 | 18.70 Mn |
| Sep 30, 2025 | 18.70 Mn |
| Jun 30, 2025 | -7.09 Mn |
| Jun 30, 2025 | -7.09 Mn |
| Mar 31, 2025 | -6.58 Mn |
| Mar 31, 2025 | -6.58 Mn |
| Dec 31, 2024 | -5.76 Mn |
| Dec 31, 2024 | -5.76 Mn |
| Sep 30, 2024 | -5.23 Mn |
| Sep 30, 2024 | -5.23 Mn |
| Jun 30, 2024 | -6.15 Mn |
| Jun 30, 2024 | -6.15 Mn |
| Mar 31, 2024 | -6.65 Mn |
| Mar 31, 2024 | -6.65 Mn |